Compare Barclays PLC (BCS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs IDEXX Laboratories, Inc. — how do they compare? Barclays PLC trades at $28.12 (market cap $93.87B), while IDEXX Laboratories, Inc. trades at $573.36 (market cap $46.22B). The key difference: Barclays PLC is far larger — about 2× IDEXX Laboratories, Inc.'s market cap, and Barclays PLC pays a 2.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BCS | IDXX | |
|---|---|---|
Market Cap | $93.87B | $46.22B |
Sector | Financials | Health |
52-Week High | $28.56 | $766.68 |
52-Week Low | $19.36 | $526.44 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.08, up 0.36% today, with a bullish technical signal from moving averages and a P/B ratio below 1 at 0.88, indicating potential undervaluation. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.90 surpassing the $0.89 estimate, while revenue growth accelerated to $29.14 billion in 2025. However, the stock faces headwinds from a securities class action investigation and concerns over cost pressures highlighted in recent analyst reports.
The outlook for BCS is cautiously optimistic, supported by strong profitability with a net income margin of 25.51% and analyst consensus favoring Buy ratings (68%). Key risks include ongoing legal scrutiny and rising operating expenses, but the stock's low valuation and dividend yield near 1.1% offer value for long-term investors amid stable cash flow trends.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
